研究領域與專長
  1. 臨床癌症學
  2. 癌症藥物研發
  3. 轉譯醫學
學經歷
經歷
  • 2014 – 迄今   合聘研究員, 中研院生化所
  • 2011 – 迄今   癌症生物學與藥物研發博士學位學程教授, 臺北醫學大學
  • 2011 – 2017   校長, 臺北醫學大學
  • 2003 – 2011   希望城癌症中心研究所, 教授
學歷
  • 1985 – 1988   博士, 病理及細胞生物學, 湯瑪士傑佛遜醫學大學
  • 1975 – 1982   醫學士, 醫學系, 臺北醫學大學
主要著作
Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials.
Liu JW, Chen C, Loh EW, Chu CC, Wang MY, Ouyang HJ, Chang YT, Zhuang WZ, Chou CW, Huang DJ, Lee CH, Yen Y, Tam KW.
Curr Med Res Opin. (2018)
Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
Luu T, Kim KP, Blanchard S, Anyang B, Hurria A, Yang L, Beumer JH, Somlo G, Yen Y.
Breast Cancer Res Treat. (2018)
Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors.
Hsieh TH, Liu YR, Chang TY, Liang ML, Chen HH, Wang HW, Yen Y, Wong TT.
Neuro Oncol. (2018)
1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma.
Liu YM, HuangFu WC, Huang HL, Wu WC, Chen YL, Yen Y, Huang HL, Nien CY, Lai MJ, Pan SL, Liou JP.
Eur J Med Chem. (2017)
Benzodiazepines use and breast cancer risk: A population-based study and gene expression profiling evidence.
Iqbal U, Chang TH, Nguyen PA, Syed-Abdul S, Yang HC, Huang CW, Atique S, Yang WC, Moldovan M, Jian WS, Hsu MH, Yen Y, Jack Li YC.
J Biomed Inform. (2017)
Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
Ding J, Kuo ML, Su L, Xue L, Luh F, Zhang H, Wang J, Lin TG, Zhang K, Chu P, Zheng S, Liu X, Yen Y.
Carcinogenesis. (2017)
Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1a co-activator driving oral cancer progression.
Jing-Wen Shih, Wei-Fan Chiang, Alexander T.H. Wu, Ming-Heng Wu, Ling-Yu Wang, Yen-Ling Yu, Yu-Wen Hung, Wen-Chang Wang, Cheng-Ying Chu, Chiu-Lien Hung, Chun A. Changou, Yen Y & Hsing-Jien Kung.
Nature Communications. (2017)
Mechanism and Clinical Properties of StemBios Cell Therapy: Induction of Early Osseointegration in Novel Dental Implants.
Weng CC, Ou KL, Wu CY, Huang YH, Wang J, Yen Y, Cheng HY, Lin YH.
Int J Oral Maxillofac Implants. (2017)
Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways.
Huang YJ, Yang CK, Wei PL, Huynh TT, Whang-Peng J, Meng TC, Hsiao M, Tzeng YM, Wu AT, Yen Y.
J Hematol Oncol. (2017)
Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis.
Guosong Shen, Pingya He, Yingying Mao, Peipei Li, Frank Luh, Guohui Ding, Xiyong Liu, Yun Yen.
Breast Cancer (2017)
著作列表

https://tmu.pure.elsevier.com/zh/persons/yun-yen-2/publications/

  1. 臨床癌症學
  2. 癌症藥物研發
  3. 轉譯醫學
經歷
  • 2014 – 迄今   合聘研究員, 中研院生化所
  • 2011 – 迄今   癌症生物學與藥物研發博士學位學程教授, 臺北醫學大學
  • 2011 – 2017   校長, 臺北醫學大學
  • 2003 – 2011   希望城癌症中心研究所, 教授
學歷
  • 1985 – 1988   博士, 病理及細胞生物學, 湯瑪士傑佛遜醫學大學
  • 1975 – 1982   醫學士, 醫學系, 臺北醫學大學
Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials.
Liu JW, Chen C, Loh EW, Chu CC, Wang MY, Ouyang HJ, Chang YT, Zhuang WZ, Chou CW, Huang DJ, Lee CH, Yen Y, Tam KW.
Curr Med Res Opin. (2018)
Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
Luu T, Kim KP, Blanchard S, Anyang B, Hurria A, Yang L, Beumer JH, Somlo G, Yen Y.
Breast Cancer Res Treat. (2018)
Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors.
Hsieh TH, Liu YR, Chang TY, Liang ML, Chen HH, Wang HW, Yen Y, Wong TT.
Neuro Oncol. (2018)
1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma.
Liu YM, HuangFu WC, Huang HL, Wu WC, Chen YL, Yen Y, Huang HL, Nien CY, Lai MJ, Pan SL, Liou JP.
Eur J Med Chem. (2017)
Benzodiazepines use and breast cancer risk: A population-based study and gene expression profiling evidence.
Iqbal U, Chang TH, Nguyen PA, Syed-Abdul S, Yang HC, Huang CW, Atique S, Yang WC, Moldovan M, Jian WS, Hsu MH, Yen Y, Jack Li YC.
J Biomed Inform. (2017)
Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
Ding J, Kuo ML, Su L, Xue L, Luh F, Zhang H, Wang J, Lin TG, Zhang K, Chu P, Zheng S, Liu X, Yen Y.
Carcinogenesis. (2017)
Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1a co-activator driving oral cancer progression.
Jing-Wen Shih, Wei-Fan Chiang, Alexander T.H. Wu, Ming-Heng Wu, Ling-Yu Wang, Yen-Ling Yu, Yu-Wen Hung, Wen-Chang Wang, Cheng-Ying Chu, Chiu-Lien Hung, Chun A. Changou, Yen Y & Hsing-Jien Kung.
Nature Communications. (2017)
Mechanism and Clinical Properties of StemBios Cell Therapy: Induction of Early Osseointegration in Novel Dental Implants.
Weng CC, Ou KL, Wu CY, Huang YH, Wang J, Yen Y, Cheng HY, Lin YH.
Int J Oral Maxillofac Implants. (2017)
Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways.
Huang YJ, Yang CK, Wei PL, Huynh TT, Whang-Peng J, Meng TC, Hsiao M, Tzeng YM, Wu AT, Yen Y.
J Hematol Oncol. (2017)
Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis.
Guosong Shen, Pingya He, Yingying Mao, Peipei Li, Frank Luh, Guohui Ding, Xiyong Liu, Yun Yen.
Breast Cancer (2017)

https://tmu.pure.elsevier.com/zh/persons/yun-yen-2/publications/